Navigation Links
AbbVie Reports Second-Quarter 2014 Financial Results
Date:7/25/2014

mphoma (NHL), including diffuse large B-cell lymphoma (DLBCL).  ABT-199/GDC-0199 as a monotherapy in patients with relapsed/refractory CLL harboring the 17p deletion is under investigation in an ongoing Phase 2 clinical trial.
  • Also at ASCO, AbbVie released preliminary results from an ongoing Phase 1 study of ABT-414, an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate, in combination with temozolomide, which showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiforme.  The trial was designed to evaluate the toxicities, pharmacokinetics and recommended Phase 2 dose of ABT-414 when administered every other week in combination with temozolomide in patients with recurrent or unresectable glioblastoma.  Other important assessments included adverse events, pharmacokinetic parameters, objective response and tumor tissue epidermal growth factor receptor biomarkers.
  • The New Drug Application for AbbVie's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 hepatitis C virus (HCV) infection was accepted by the U.S. Food and Drug Administration (FDA) and granted priority review.  Additionally, the Marketing Authorization Applications for AbbVie's HCV regimen were validated and are under accelerated assessment by the European Medicines Agency (EMA). 
  • AbbVie and Bristol-Myers Squibb announced that the FDA has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with lenalidomide and dexamethasone for the treatment of multiple myeloma in patients who have received one or more prior therapies.  Phase 3 studies are ongoing and expected to complete in 2015.
  • On June 19, the AbbVie board of directors declared a quarterly cash dividend of $0.42 per share, payable Aug. 15, 2014 to stockho
    '/>"/>

  • SOURCE AbbVie
    Copyright©2014 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

    Related medicine technology :

    1. AbbVie to Host Second-Quarter Earnings Conference Call
    2. AbbVie to Host Fourth-Quarter and Full-Year 2013 Earnings Conference Call
    3. AbbVie Demonstrates 96 percent SVR(12) in its Phase III Study of Treatment-Experienced Patients with Genotype 1 Hepatitis C
    4. AbbVie Releases First of Six Phase III Results from Investigational All-Oral, Interferon-Free, 12-week Regimen, Showing 96 Percent SVR12 in Genotype 1 Hepatitis C Patients New to Therapy
    5. U.S. Gastroenterologists Have Increased Their TNF-alpha Inhibitor Use Since 2012, Especially for AbbVies Humira, as a Result of Its Recent Approval in Ulcerative Colitis
    6. Financial Results, New Drug Applications, and Stock Price Movements - Research Report on Endo, Bristol-Myers Squibb, Express Scripts, AbbVie, and Incyte
    7. AbbVie Reports Third-Quarter 2013 Financial Results
    8. AbbVie Named a Science Top Employer
    9. AbbVie To Present Investigational Data From Phase II Hepatitis C Program At The Liver Meeting
    10. AbbVie and Galapagos to Co-Develop Cystic Fibrosis Therapies
    11. Strong Sales and Healthcare Reforms Benefit Earnings - Research Report on Gilead, Pfizer, Merck, AbbVie, and LifePoint
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/22/2015)...  ResMed Inc. (NYSE: RMD ) today announced results ... quarter was $423.0 million, a 10 percent increase compared to ... on a constant currency basis). Net income was $91.2 million, ... December 31, 2013. Diluted earnings per share for the quarter ...
    (Date:1/22/2015)... , Jan. 22, 2015  Bio-Techne Corporation (NASDAQ: ... Ella, the first member of the new Simple Plex ... brand.  This launch represents the re-branding of the previously ... Simple Plex platform is a transformative immunoassay technology which ...
    (Date:1/22/2015)... Markets ( http://www.researchandmarkets.com/research/3h534b/infectious ) has announced the ... Product, Application, Technology, End User - Global Forecast to ... The infectious disease diagnostics market is expected to grow ... 2019 from $12,422.8 million in 2014. Increase in governmental ...
    Breaking Medicine Technology:ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 2ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 3ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 4ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 5ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 6ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 7ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 8ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 9ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 10ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2015 11Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3
    (Date:1/22/2015)... Plainsboro, NJ (PRWEB) January 22, 2015 ... advocate and keynote speaker at the upcoming 32nd ... by ACCME-accredited Physicians’ Education Resource®, LLC (PER®) , ... breast would have gone undetected if she had not ...
    (Date:1/22/2015)... has added many trendy Champagne wedding dresses to ... the past three years. Today, the business announces a special ... the sales manager of the company, this is on the ... point can be reflected on the discounted wedding dresses from ...
    (Date:1/22/2015)... WASHINGTON, DC (PRWEB) January 22, 2015 ... conditions in vulnerable communities and cause financial distress to ... report by analysts at Howard University’s Center on Race ... of dollars in economic activity, payday loans at the ...
    (Date:1/22/2015)... 2015 JJsHouse.com is a famous dress online ... business announces its latest collection of wedding dresses , ... important issue is the wedding dress on your big day; ... woman’s life. Every bride wants to find the most suitable ...
    (Date:1/22/2015)... VA (PRWEB) January 22, 2015 Step ... power at the Science Museum of Virginia. Wicked Plants, ... , Wicked Plants unearths 75 poisonous, carnivorous and diabolical ... through each room to uncover the biochemical, physical and ...
    Breaking Medicine News(10 mins):Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 2Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 3Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 4Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 5Health News:Joan Lunden Reveals Diagnostic Approach That Led To Early Detection;To Keynote 32nd Annual Miami Breast Cancer Conference® 6Health News:Weddingshe Announces A Special Offer On Its Popular Glamorous Wedding Dresses 2Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Find The Most Suitable Wedding Dress At JJsHouse.com 2Health News:Wicked Plants are taking over the Science Museum of Virginia 2
    ... future of drug design lies in developing therapies that can ... areas of the nervous system. Scientists at the Universities of ... drugs to target specific areas of the brain. ... of Physiology and Pharmacology and published in this week,s ...
    ... This press release is available in German . ... a mirror-inverted manner. They differ from each other like a ... that is referred to as chirality is of particular relevance ... carbon dioxide or methane are not chiral, many biologically relevant ...
    ... new type of therapy aimed at reversing the gene-silencing ... a small clinical trial conducted by researchers at the ... cancer patients who received a two-drug combination designed to ... than the expected four months, and two patients showed ...
    ... HealthDay Reporter , WEDNESDAY, Nov. 9 (HealthDay News) -- ... the researchers appear to have successfully screened for a rare ... blood test. By performing a DNA analysis on a ... able to accurately identify a specific chromosomal irregularity called "fetal ...
    ... York, NY (November 10, 2011)A new national initiative, IPAL-EM ... increase the use of palliative care when seriously ill ... Despite growing recognition of the role of the palliative ... often seem like a challenge of cultures and mindset. ...
    ... June, a law took effect in the state of ... ownership. In September, a federal judge granted a preliminary ... law impeded doctors, Constitutional right to freedom of speech. ... the American Journal of Preventive Medicine reviews ...
    Cached Medicine News:Health News:Scientists discover how to design drugs that could target particular nerve cells 2Health News:Flexible rack systems sort molecules 2Health News:Combination epigenetic therapy clinical trial results 2Health News:Combination epigenetic therapy clinical trial results 3Health News:Maternal Blood Test Might Spot Birth Defects More Safely 2Health News:Maternal Blood Test Might Spot Birth Defects More Safely 3Health News:IPAL-EM launches to improve palliative care in emergency medicine 2Health News:Discussions of guns in the home part of comprehensive preventive health care 2
    1.5 mm inner cutting edge....
    Phaco chopper & iris retractor 2 mm cutting edge....
    Round handle dull finish. For right handed surgeon....
    Cross action, round handle, maximum opening 2.8 mm....
    Medicine Products: